A lady receives a vaccination in opposition to the brand new coronavirus an infection. File |Picture Credit score: Vijay Soneji
The Central Data Fee (CIC) has directed the Division for Promotion of Trade and Intratrade (DPIIT) to submit an affidavit stating that data on authorities funds supplied to COVID-19 vaccine producers through the pandemic was “not accessible”.
The instructions had been introduced through the listening to of a Proper to Data (RTI) enchantment filed by Mahavir Singh Sharma, who had sought particulars of a whole lot of billions of rupees launched by the Union authorities to the Serum Institute of India and Bharat Biotech for the manufacturing of COVID-19 vaccines in 2020 and 2021.
In its reply to the RTI utility, DPIIT mentioned the knowledge sought was not in its possession.
“Concerning your RTI utility on the above topic, the required data sought shouldn’t be accessible from the logistics division, DPIIT. Subsequently, the required data could also be handled as ‘NIL’,” the ministry mentioned. The First Appellate Authority later upheld this reply.
In his order, Data Commissioner Khushwant Singh Sethi identified that the logistics division had clearly knowledgeable the applicant that the knowledge was not accessible.
Nonetheless, the Fee directed public authorities to formally verify their place by affidavits.
“The accused individuals are directed to submit an affidavit to the fee containing a categorical assertion that the knowledge sought within the RTI utility dated October 6, 2023 shouldn’t be accessible in public authorities,” the CIC mentioned.
The fee mentioned that whereas DPIIT’s response was acceptable, it wanted an affidavit to placed on file the division’s competition that the knowledge was not accessible earlier than disposing of the enchantment.
It directed the DPIIT to submit the affidavit each by submit and by importing it on the CIC’s compliance portal inside 15 days and likewise ship a replica to the appellant (Mr. Sharma).
In his RTI utility, Sharma had sought data that “Rs 45 billion launched by the Authorities of India to the Serum Institute and Bharat Biotech through the COVID-19 outbreak with out financial institution ensures has been returned to the Authorities of India with curiosity or the 2 institutes have handed over vaccine doses in lieu of the quantity acquired from the federal government.”
He additionally sought data exhibiting that “the Authorities of India has acquired all doses of vaccines taken from the Serum Institute and Bharat Biotech to struggle the COVID-19 pandemic”, particulars of vaccines despatched overseas “with the permission of the Authorities of India”, and “full particulars of the quantities acquired by each institutes in trade for vaccines from overseas”.
The applicant additional requested whether or not “all Indian residents have been administered Covaxin and Covaxin vaccines or whether or not some Indian residents have been excluded”, “the full quantity spent by the Authorities of India on the acquisition of Covaxin and Covaxin” and whether or not different coronavirus vaccines have been bought for Indian residents.
Through the listening to, DPIIT officers claimed that the knowledge was not held by their division and that the RTI utility was initially filed with one other division (Biotechnology Division) after which forwarded.
